Summarized by Masters of Longevity from BioAge Labs.
In its May 2026 quarterly update, BioAge reported that a January offering and February option exercise raised approximately $132.3 million in gross proceeds.
Key Takeaways
- The total includes the underwriters’ option, exercised in full in February 2026.
- The financing supports development of BGE-102 and BioAge’s broader pipeline.
- This is a May recap of earlier financing, not a newly announced May funding round.
